Alnylam Pharmaceuticals (ALNY) Capital Expenditures (QoQ) (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) Capital Expenditures (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,681.27 Bn 66,680.98 Bn -
2 Nanobiotix 1,942.19 Bn 1,942.13 Bn -
3 Akari Therapeutics 1,132.35 Bn 1,132.35 Bn -
4 BeOne Medicines 475.46 Bn 470.67 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.19 Bn 115.94 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.44 Bn 60.69 Bn 3.31 Bn
7 Belite Bio 63.20 Bn 63.20 Bn -
8 Argenx Se 57.08 Bn 51.90 Bn 1.41 Bn
9 Revolution Medicines 38.11 Bn 38.11 Bn -
10 Alnylam Pharmaceuticals 37.30 Bn 34.29 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -55.53%
Dec 31, 2025 459.42%
Sep 30, 2025 -195.56%
Jun 30, 2025 59.34%
Mar 31, 2025 -1.36%
Dec 31, 2024 -62.30%
Sep 30, 2024 2,145.80%
Jun 30, 2024 -152.59%
Mar 31, 2024 105.20%
Dec 31, 2023 -352.15%
Sep 30, 2023 7.37%
Jun 30, 2023 14.60%
Mar 31, 2023 -78.92%
Dec 31, 2022 337.42%
Sep 30, 2022 -272.89%
Jun 30, 2022 -10.10%
Mar 31, 2022 143.68%
Dec 31, 2021 -256.88%
Sep 30, 2021 23.31%
Jun 30, 2021 189.96%